Hugel (145020) Q3 2025 earnings summary

Executive summary

• Net sales for 3Q25 reached KRW 105.9bn, up 0.8% year-over-year, with gross profit at KRW 81.7bn, down 1.4% year-over-year.

• Operating profit declined 11.2% year-over-year to KRW 47.4bn, and net income fell 9.5% to KRW 38.0bn.

Financial highlights

• Gross margin was 77.1%, a decrease of 1.7 percentage points year-over-year.

• SG&A expenses increased 16.2% year-over-year to KRW 34.3bn.

• Pre-tax income was KRW 51.1bn, down 3.6% year-over-year.

Segment performance

• Botulinum Toxin sales declined 7% year-over-year, representing 57% of product mix.

• Dermal Filler & Skinbooster sales grew 1% and 65% year-over-year, accounting for 29% and 14% of mix, respectively.

• Thread & Others segment dropped 61% year-over-year, now 1% of mix.